Rituximab for Non-Hodgkin's Lymphoma

M D Anderson Cancer Center, Houston, TX
Non-Hodgkin's LymphomaRituximab - Biological
All Sexes
What conditions do you have?

Study Summary

This trial is testing rituximab, lenalidomide, acalabrutinib, tafasitamab to see if they can help control non-germinal center diffuse large B-cell lymphoma.

Eligible Conditions
  • Non-Hodgkin's Lymphoma

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: Time between study entry and death from any cause, assessed up to 2 years post-treatment

Day 21
Complete response rate
Day 21
Overall response rate
Year 2
Progression free survival
Year 2
Overall survival
Day 30
Incidence of adverse events (AEs)

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Side Effects for

8%Mild/moderate allergic reactions
3%Severe allergic reaction
This histogram enumerates side effects from a completed 2016 Phase 2 & 3 trial (NCT03002038) in the Rituximab ARM group. Side effects include: Mild/moderate allergic reactions with 8%, Severe allergic reaction with 3%.

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.
Approved for 50 Other Conditions
This treatment demonstrated efficacy for 50 other conditions.

Trial Design

1 Treatment Group

Treatment (uLTRA, CHOP)
1 of 1

Experimental Treatment

60 Total Participants · 1 Treatment Group

Primary Treatment: Rituximab · No Placebo Group · Phase 2

Treatment (uLTRA, CHOP)Experimental Group · 8 Interventions: Vincristine, Prednisone, Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Tafasitamab, Acalabrutinib, Lenalidomide · Intervention Types: Drug, Drug, Biological, Drug, Drug, Biological, Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved
FDA approved
FDA approved
FDA approved
FDA approved
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: time between study entry and death from any cause, assessed up to 2 years post-treatment

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,849 Previous Clinical Trials
1,793,465 Total Patients Enrolled
Jason WestinPrincipal InvestigatorM.D. Anderson Cancer Center
3 Previous Clinical Trials
135 Total Patients Enrolled
Jason Westin, MDPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
80 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You can take a low dose of aspirin or other medication as a blood thinner.

Frequently Asked Questions

What other clinical examinations have been conducted utilizing Rituximab?

"At present, 1750 clinical trials are being conducted to study the efficacy of Rituximab. Of these, 377 have entered Phase 3 and can be found across 69161 locations with a majority in Joliet, Illinois." - Anonymous Online Contributor

Unverified Answer

Has the FDA sanctioned Rituximab as a safe and effective drug?

"The safety of Rituximab has been estimated by the Power team to be a 2, as its efficacy is yet unproven but some supporting data exists for its safety." - Anonymous Online Contributor

Unverified Answer

What types of treatments is Rituximab commonly prescribed for?

"Rituximab can be employed to treat pheochromocytomas, ulcerative colitis, as well as varicella-zoster virus acute retinal necrosis." - Anonymous Online Contributor

Unverified Answer

Are there opportunities to become involved in this investigation?

"Affirmative. Clinicaltrials.gov data corroborates that this research is actively recruiting, with the first listing being posted on March 3rd 2022 and last update occurring on July 10th of the same year. The study requires 60 individuals from a single medical facility to participate in its activities." - Anonymous Online Contributor

Unverified Answer

What is the scope of subjects currently under evaluation in this clinical exploration?

"Affirmative. According to information in clinicaltrials.gov, this medical study initially opened for recruitment on March 3rd 2022 and has recently been updated on July 10th 2022. This research requires 60 participants based at a single site." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.